INSP Inspire Medical Systems, Inc.
USHealthcareAs of 2026-08-24
Why INSP matters now
Inspire Medical Systems, Inc. (INSP) is a US stock in Healthcare. The latest InvestLog snapshot shows $61.50 with -1.38% on the session and $1.78B in market capitalization; recent performance reads 1-month +0.19% and YTD -53.80%.
The latest financial table shown here is Q1 2026, with revenue of $204.6M, net income of $-11.3M, and EPS of $-0.39. Investors can compare that operating picture with valuation signals such as P/E 10.70 and FCF yield 7.9%.
The latest indexable market news headline is "Deutsche Bank AG Makes New $7.86 Million Investment in Inspire Medical Systems, Inc. INSP" from Defense World.
Additional event context on this page matters because analyst consensus is Hold with a median target of $55.00; recent insider activity includes Rondoni John filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
10.70
PEG
0.06
P/B
1.54
P/S
1.34
EV/EBITDA
14.46
DCF Value
$160.79
FCF Yield
7.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
85.8%
Operating Margin
5.6%
Net Margin
14.3%
ROE
18.0%
ROA
14.4%
ROIC
6.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $204.6M | $-11.3M | $-0.39 |
| Q4 2025 | $269.1M | $136.1M | $4.66 |
| FY 2025 | $912.0M | $145.4M | $4.89 |
| Q3 2025 | $224.5M | $9.9M | $0.34 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$57.36
Target (Median)
$55.00
Target Range
$39.00 - $70.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.73
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.